Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PARG | Q86W56 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17347731 | 1.00 | CA12 (0.49) | CA12CA9PARGALDH1A1HTT | |
| SCHEMBL17347732 | 1.00 | CA12 (0.49) | CA12CA9PARGALDH1A1HTT | |
| SCHEMBL17335895 | 0.85 | PARG (0.48) | PARGALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL17335925 | 0.83 | CA12 (0.49) | CA12CA9PARGALDH1A1HTT | |
| SCHEMBL17335927 | 0.83 | CA12 (0.49) | CA12CA9PARGALDH1A1HTT | |
| SCHEMBL17335935 | 0.83 | CA12 (0.49) | CA12CA9PARGALDH1A1HTT | |
| SCHEMBL17335962 | 0.83 | CA12 (0.49) | CA12CA9PARGALDH1A1HTT | |
| SCHEMBL18763280 | 0.83 | CA12 (0.49) | CA12CA9PARGALDH1A1HTT | |
| SCHEMBL17335991 | 0.81 | METAP2 (0.46) | PARGALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL17335948 | 0.80 | ERCC1 (0.58) | CA12CA9PARGALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015189595-A1 | TREATMENT OF CHAGAS DISEASE | UNIVERSITY OF DUNDEE (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | CXCR4, CBR1, CHRM1 | CA12 2487/4885CA9 2540/4885PARG 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.